Frequency of Hyperinsulinemia and Its Relationship with Adiposity and Body Composition in Adolescents and Young Adults Aged 16-25 in Mumbai - Top-Institutions - MDSpire

Frequency of Hyperinsulinemia and Its Relationship with Adiposity and Body Composition in Adolescents and Young Adults Aged 16-25 in Mumbai

  • By

  • Panchali Moitra

  • Jagmeet Madan

  • Soumik Kalita

  • Sharvari Desai

  • Shobha A. Udipi

  • Rama Vaidya

  • March 13, 2026

  • 0 min

Share

Top Institutions in Endocrinology

Brief introduction explaining scope and methodology.

  • #1

    Joslin Diabetes Center
    Joslin Diabetes Center

    Boston, MA

    Key Differentiators

    • Endocrinology
    • Diabetes Research
    • Metabolic Disorders

  • #2

    Mayo Clinic
    Mayo Clinic

    Rochester, MN

    Key Differentiators

    • Endocrinology
    • Pediatric Diabetes
    • Obesity Research

  • #3

    All India Institute of Medical Sciences (AIIMS)
    All India Institute of Medical Sciences (AIIMS)

    New Delhi, Delhi

    Key Differentiators

    • Endocrinology
    • Diabetes Research
    • Public Health

  • #4

    Harvard T.H. Chan School of Public Health
    Harvard T.H. Chan School of Public Health

    Boston, MA

    Key Differentiators

    • Epidemiology
    • Nutrition
    • Metabolic Disease Research

  • #5

    Stanford University School of Medicine
    Stanford University School of Medicine

    Stanford, CA

    Key Differentiators

    • Endocrinology
    • Pediatric Metabolism
    • Diabetes Research

Original Source(s)

Frequency of Hyperinsulinemia and Its Relationship with Adiposity and Body Composition in Adolescents and Young Adults Aged 16-25 in Mumbai

  • by Panchali Moitra, Jagmeet Madan, Soumik Kalita, Sharvari Desai, Shobha A. Udipi, Rama Vaidya

  • March 13, 2026

Related Content

Reorienting catch-up growth research toward early-life prevention of metabolic disorders using natural products

Texas Emerges as Focus of New Trump Administration Actions to Limit Gender-Affirming Care

Retatrutide Shows 28% Weight Loss in Phase 3 Trial

Nearly half of participants receiving the highest dose achieved at least 30% body weight reduction.